Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Chaftari, Anne Marie ^a   Hachem, Ray ^a   Reitzel, Ruth ^a   Jordan, Mary ^a   Jiang, Ying ^a   Yousif, Ammar ^a   Garoge, Kumait ^a   Deshmukh, Poonam ^a   Al Hamal, Zanaib ^a   Jabbour, Joseph ^a   Hanania, Alexander ^a   Raad, Sammy ^a   Jamal, Mohamed ^a   Raad, Issam ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PROCALCITONIN; CALCA PROTEIN, HUMAN; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; PROTEIN PRECURSOR; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEPSIS; BLOOD; DISEASE COURSE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CALCITONIN; CALCITONIN GENE-RELATED PEPTIDE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MIDDLE AGED; NEOPLASMS; PROTEIN PRECURSORS; YOUNG ADULT;

EID: 84940191162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130999     Document Type: Article

References (33)

1. Kretzschmar M, Kruger A, Schirrmeister W. Procalcitonin following elective partial liver resection - origin from the liver? Acta Anaesthesiol Scand. 2001; 45(9):1162-7. Epub 2001/10/31. doi: 450918 [pii]. PMID: 11683669.
2. Oberhoffer M, Vogelsang H, Jager L, Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care. 1999; 14(1):29-33. Epub 1999/04/02. doi: S0883-9441(99)90005-9 [pii]. PMID: 10102721.
3. Bihan H, Becker KL, Snider RH, Nylen E, Vittaz L, Lauret C, et al. Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid. 2003; 13(8):819-22. Epub 2003/10/16. doi: 10.1089/105072503768499716 PMID: 14558925.
4. Gilbert DN. Procalcitonin as a biomarker in respiratory tract infection. Clin Infect Dis. 2011; 52 Suppl 4: S346-50. Epub 2011/04/06. doi: cir050 [pii] doi: 10.1093/cid/cir050 PMID: 21460294.
5. Shomali W, Hachem R, Chaftari AM, Jiang Y, Bahu R, Jabbour J, et al. Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? Cancer. 2012; 118(23):5823-9. Epub 2012/05/19. doi: 10.1002/cncr.27602 PMID: 22605389.
6. Al Shuaibi M, Bahu RR, Chaftari AM, Al Wohoush I, Shomali W, Jiang Y, et al. Pro-adrenomedullin as a novel biomarker for predicting infections and response to antimicrobials in febrile patients with hematologic malignancies. Clin Infect Dis. 2013; 56(7):943-50. Epub 2013/01/05. doi: 10.1093/cid/cis1029cis1029 [pii]. PMID: 23288950.
7. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011; 171(15):1322-31. Epub 2011/08/10. doi: 171/15/1322 [pii] doi: 10.1001/archinternmed.2011.318 PMID: 21824946.
8. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab. 2004; 89(4):1512-25. Epub 2004/04/09. PMID: 15070906.
9. Matzaraki V, Alexandraki KI, Venetsanou K, Piperi C, Myrianthefs P, Malamos N, et al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem. 2007; 40(5-6):336-42. Epub 2007/02/20. doi: S0009-9120(06)00376-6 [pii] doi: 10.1016/j.clinbiochem.2006.10.027 PMID: 17306245.
10. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol. 2006; 63(5):321-9. Epub 2006/04/28. doi: SJI1750 [pii] doi: 10.1111/j.1365-3083.2006.01750.x PMID: 16640655.
11. Kutteh WH, Rainey WE, Carr BR. Regulation of interleukin-6 production in human fetal Kupffer cells. Scand J Immunol. 1991; 33(5):607-13. Epub 1991/05/01. PMID: 2031150.
12. Liu XH, Kirschenbaum A, Lu M, Yao S, Klausner A, Preston C, et al. Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway. Biochem Biophys Res Commun. 2002; 290(1):249-55. Epub 2002/01/10. doi: 10.1006/bbrc.2001.6188 S0006291X01961881 [pii]. PMID: 11779161.
13. Chang CY, Li MC, Liao SL, Huang YL, Shen CC, Pan HC. Prognostic and clinical implication of IL-6 expression in glioblastoma multiforme. J Clin Neurosci. 2005; 12(8):930-3. Epub 2005/12/06. doi: S0967-5868(05)00295-X [pii] doi: 10.1016/j.jocn.2004.11.017 PMID: 16326273.
14. Tamm I, Cardinale I, Kikuchi T, Krueger JG. E-cadherin distribution in interleukin 6-induced cell-cell separation of ductal breast carcinoma cells. Proc Natl Acad Sci U S A. 1994; 91(10):4338-42. Epub 1994/05/10. PMID: 8183909; PubMed Central PMCID: PMC43780.
15. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Critical care medicine. 2003; 31(4):1250-6. doi: 10.1097/01.CCM.0000050454.01978.3B PMID: 12682500.
16. Vincent JL, Martinez EO, Silva E. Evolving concepts in sepsis definitions. Critical care clinics. 2009; 25(4):665-75, vii. doi: 10.1016/j.ccc.2009.07.001 PMID: 19892246.
17. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011; 52(4):e56-93. doi: 10.1093/cid/cir073 PMID: 21258094.
18. Brahms. PCT Sensitive Kryptor "Instructions for Use". Thermo Scientific Brahms LLC. Version 10 ed. Middletown VA, USA2011.
19. Keramidaris D, Koronakis N, Lagoudianakis EE, Pappas A, Koukoutsis I, Chrysikos I, et al. Procalcitonin in patients with colorectal cancer. Journal of BUON: official journal of the Balkan Union of Oncology. 2013; 18(3):623-8. PMID: 24065474.
20. Kaczka K, Mikosinski S, Fendler W, Jalocha-Kaczka A, Pomorski L. Can procalcitonin be useful for medullary thyroid cancer? Endokrynologia Polska. 2010; 61(5):430-6. PMID: 21049453.
21. Carnino L, Betteto S, Loiacono M, Chiappella A, Giacobino A, Ciuffreda L, et al. Procalcitonin as a predictive marker of infections in chemoinduced neutropenia. Journal of cancer research and clinical oncology. 2010; 136(4):611-5. doi: 10.1007/s00432-009-0699-9 PMID: 19876647.
22. Massaro KS, Costa SF, Leone C, Chamone DA. Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis. 2007; 7:137. Epub 2007/11/24. doi: 1471-2334-7-137 [pii] doi: 10.1186/1471-2334-7-137 PMID: 18034890; PubMed Central PMCID: PMC2217552.
23. Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis. 1999; 18(4):283-5. Epub 1999/06/29. PMID: 10385017.
24. Engel A, Steinbach G, Kern P, Kern WV. Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis. 1999; 31(2):185-9. Epub 1999/08/14. PMID: 10447330.
25. Yaegashi H, Izumi K, Kitagawa Y, Kadono Y, Konaka H, Mizokami A, et al. Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. International journal of urology: official journal of the Japanese Urological Association. 2014; 21(1):104-6. doi: 10.1111/iju.12178 PMID: 23600524.
26. Bele N, Darmon M, Coquet I, Feugeas JP, Legriel S, Adaoui N, et al. Diagnostic accuracy of procalcitonin in critically ill immunocompromised patients. BMC Infect Dis. 2011; 11:224. doi: 10.1186/1471-2334-11-224 PMID: 21864380; PubMed Central PMCID: PMC3170614.
27. Mauro MV, Cavalcanti P, Perugini D, Noto A, Sperli D, Giraldi C. Diagnostic utility of LightCycler Septi-Fast and procalcitonin assays in the diagnosis of bloodstream infection in immunocompromised patients. Diagnostic microbiology and infectious disease. 2012; 73(4):308-11. doi: 10.1016/j.diagmicrobio.2012.04.006 PMID: 22626731.
28. Hutchins D, Steel CM. Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors. Int J Cancer. 1994; 58(1):80-4. Epub 1994/07/01. PMID: 7516927.
29. de Jong KP, van Gameren MM, Bijzet J, Limburg PC, Sluiter WJ, Slooff MJ, et al. Recombinant human interleukin-6 induces hepatocyte growth factor production in cancer patients. Scand J Gastroenterol. 2001; 36(6):636-40. Epub 2001/06/27. PMID: 11424323.
30. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996; 271(2):736-41. Epub 1996/01/12. PMID: 8557680.
31. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999; 19(2B):1427-32. Epub 1999/06/12. PMID: 10365118.
32. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, et al. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 1996; 56(12):2776-80. Epub 1996/06/15. PMID: 8665513.
33. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res. 1996; 2(8):1405-9. Epub 1996/08/01. PMID: 9816314.